SereNeuro Therapeutics, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

SereNeuro Therapeutics, Inc. - overview

Established

2024

Location

Baltimore, Maryland, US

Primary Industry

Biotechnology

About

Founded in 2024 by CEO Daniel Saragnese and and based in Maryland, US, SereNeuro Therapeutics, Inc. develops SN101, an iPSC-derived cell therapy for chronic osteoarthritis joint pain, and SN102, a gene therapy for trigeminal neuralgia. In October 2026, SereNeuro Therapeutics, Inc. raised pre-seed funding.


SereNeuro Therapeutics is a preclinical biotechnology company developing non-opioid therapies for chronic pain. Its pipeline includes SN101, a first-in-class induced pluripotent stem cell (iPSC)-derived nociceptor therapy for chronic osteoarthritis joint pain that aims to both absorb pain signals and preserve cartilage, and SN102, an in vivo gene therapy for trigeminal neuralgia designed to dampen hyperactive pain-sensing neurons while preserving normal sensation and motor function. The company focuses on developing disease-modifying cell and gene therapies that address chronic pain without the use of opioids. SereNeuro Therapeutics is a preclinical-stage biotechnology company and is not yet marketing approved products.


Its future revenue streams are expected to include licensing and partnership agreements for its cell and gene therapy technologies, milestone and research collaboration payments, grants and commercialization funding, and, upon successful regulatory approval, sales of its non-opioid chronic pain therapies. The company plans to use the October 2026 funding to prepare its lead program, SN101, for IND-enabling activities while advancing its second program, SN102.


Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development

Verticals

HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.